Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Darovasertib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IDEAYA Biosciences Reports Q2 2024 Results And Business Update
    IDEAYA Biosciences Reports Q2 2024 Results And Business Update

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-inc-reports-second-quarter-2024-financial-results-and-provides-business-update-302214993.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO
    Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO

    05 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169554&sid=2

    PHARMABIZ
    05 Jun 2024
    Share Share
    IDEAYA's Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO
    IDEAYA's Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-announces-results-for-darovasertib-phase-2-ist-in-neoadjuvant-uveal-melanoma-at-asco-and-clinical-update-for-phase-2-company-sponsored-neoadjuvant-study-302161137.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation
    Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation

    23 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-abstract-summary-results-of-asco-2024-oral-presentation-for-phase-2-investigator-sponsored-study-of-darovasertib-in-neoadjuvant-uveal-melanoma-302154551.html

    PR NEWSWIRE
    23 May 2024
    Share Share
    IDEAYA's Darovasertib Uveal Melanoma Data in ASCO Oral Session
    IDEAYA's Darovasertib Uveal Melanoma Data in ASCO Oral Session

    24 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-asco-2024-oral-presentation-for-darovasertib-in-neoadjuvant-uveal-melanoma-phase-2-investigator-sponsored-study-302125242.html

    PR NEWSWIRE
    24 Apr 2024
    Share Share
    IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023
    IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023

    17 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2023-for-phase-2-clinical-data-update-for-darovasertib-and-crizotinib-combination-in-metastatic-uveal-melanoma-301958315.html

    PR NEWSWIRE
    17 Oct 2023
    Share Share